The Australian Financial Review: Jefferies, Bells prepare cancer play Clarity for $300m float

In the News

Sydney, Australia 8 June 2021 – Clarity Pharmaceuticals was featured in the Australian Financial Review, Street Talk, the leading source of breaking news in Australia’s capital markets with live updates throughout the trading day. The article discusses Clarity’s initial public offering on the Australian Securities Exchange. Read the full article here: https://www.afr.com/street-talk/jefferies-bells-prepare-cancer-play-clarity-for-250m-float-20210608-p57z40

First patient treated in Clarity’s Cu-64 SAR-bisPSMA prostate cancer trial

News, Press Releases

Sydney, Australia 10 August 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the first patient has been dosed in the 64Cu SAR-bisPSMA clinical trial in patients with confirmed prostate cancer. Clarity’s Executive Chairman, Dr Alan Taylor, commented, “We are very excited to…

Clarity commences Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial

News, Press Releases

Sydney, Australia 28 July 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has commenced its 64/67Cu SAR-bisPSMA theranostic clinical trial in patients with metastatic castrate resistant prostate cancer (mCRPC) in the US. Patient recruitment has commenced with the opening of the…

Clarity commences Cu-64 SAR-bisPSMA prostate cancer trial

News, Press Releases

Sydney, Australia 20 July 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that its 64Cu SAR-bisPSMA clinical trial in patients with confirmed prostate cancer is open for recruitment at two sites, GenesisCare CTA Medical Clinic, Perth and Nepean Hospital, Sydney. Clarity’s Executive Chairman,…

NorthStar Medical Radioisotopes Enters U.S. Supply Agreement for Commercial Supply of Therapeutic Radioisotope Copper-67 (Cu-67) Exclusively to Clarity Pharmaceuticals for its Targeted Copper Theranostics Programs

News, Press Releases

BELOIT, Wis. and Sydney, Australia – May 25, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, today announced the signing of a Master Supply…

Shaemus Gleason Appointed Executive Vice President US Operations at Clarity Pharmaceuticals

News, Press Releases

Sydney, Australia 11 May 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Shaemus Gleason as Executive Vice President U.S. Operations as the company expands its presence, clinical trials, and operations in the U.S. Shaemus joins Clarity from Bayer’s Oncology Strategic…

Clarity Pharmaceuticals’ SAR-bisPSMA patent granted in the U.S.

News, Press Releases

Sydney, Australia 6 May 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the U.S. Patent and Trademark Office (USPTO) has granted the patent application for Clarity’s SAR-bisPSMA compound and its variants. The grant of the patent application bolsters Clarity’s strong Intellectual Property…

Clarity receives US FDA clearance of IND Application for its next-generation PSMA theranostic products

News, Press Releases

Sydney, Australia 4 May 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has received a response from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug (IND) application that the study for selection and treatment of Prostate-Specific Membrane…